SSY Group Secures China Approval for Finerenone Bulk Drug Registration
SSY Group Ltd. has received approval from China's National Medical Products Administration for its Finerenone bulk drug registration. This is the second approval in China for Finerenone, used to treat chronic kidney disease in type 2 diabetes patients. The drug helps reduce risks of kidney function decline, end-stage renal disease, cardiovascular death, and heart failure hospitalization.
SSY Group Ltd. has announced that its Finerenone product has received registration approval from the National Medical Products Administration of China as a bulk drug for preparations on the market. This marks the second such approval for entities in the People’s Republic of China. Finerenone is primarily used in adult patients with chronic kidney disease associated with type 2 diabetes, helping to reduce risks of sustained decline in kidney function, end-stage renal disease, cardiovascular death, and hospitalization due to heart failure. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251205-11945789), on December 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
